Committees

Purpose: To investigate the effect of multiple treatments with ranibizumab or bevacizumab in neovascular age-related macular degeneration (AMD) using electrophysiological and anatomical measures.\udMethods: We monitored five AMD patients before and after intravitreal treatment with ranibizumab (0.5mg) or bevacizumab (1.25mg) over 8-11 months (mean 10 ±1.2 months). Three patients received ranibizumab and two patients received bevacizumab. Central and peripheral neuroretinal function was assessed using multifocal electroretinography and optical coherence tomography was used to measure central retinal thickness. Visual acuity and contrast sensitivity were assessed with Bailey-Lovie and Pelli-Robson charts.\udResults: Patients in the ranibizumab group received 5, 5 and 6 treatments and patients in the bevacizumab group received 2 treatments over a mean period of 10 months. In both groups mean peripheral neuroretinal activity transiently decreased between the treatments but not significantly whereas mean central function improved or remained stable compared to pretreatment levels after the 10 months. Central retinal thickness decreased by 163 (±14) μm and by 110 (±16) μm in the ranibizumab and bevacizumab treated group, respectively. Visual acuity improved (>3 lines) in one patients (ranibizumab group) and remained stable in four patients. Contrast sensitivity improved (>6 letters) in one patient (bevacizumab group) and remained stable in four patients.\udConclusion: Both groups show improved anatomical and central improved/stable functional outcomes compared to pretreatment after long term follow up, even though the ranibizumab group received more than twice the number of treatments than the bevacizumab group